Related references
Note: Only part of the references are listed.Errors in Data Analysis and Outcomes Coding (vol 327, pg 687, 2022)
Joshua J. Fenton
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Safety of tapentadol compared with other opioids in chronic pain treatment: network meta-analysis of randomized controlled and withdrawal trials
R. Freynhagen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry
Michael A. Ueberall et al.
PAIN MANAGEMENT (2021)
European* clinical practice recommendations on opioids for chronic noncancer pain - Part 1: Role of opioids in the management of chronic noncancer pain
Winfried Haeuser et al.
EUROPEAN JOURNAL OF PAIN (2021)
Association of Dose Tapering With Overdose or Mental Health Crisis Among Patients Prescribed Long-term Opioids
Alicia Agnoli et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Interventions to optimize prescribed medicines and reduce their misuse in chronic non-malignant pain: a systematic review
Aziza Alenezi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Beneficial opioid management strategies: A review of the evidence for the use of opioid treatment agreements
Tuesday M. McAuliffe Staehler et al.
SUBSTANCE ABUSE (2020)
Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?
Filippo Caraci et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
The Modified WHO Analgesic Ladder: Is It Appropriate for Chronic Non-Cancer Pain?
Juan Yang et al.
JOURNAL OF PAIN RESEARCH (2020)
Not All Pain is Created Equal: Basic Definitions and Diagnostic Work-Up
Cesare Bonezzi et al.
PAIN AND THERAPY (2020)
Deprescribing long-term opioid therapy in patients with chronic pain
Paul Glare et al.
INTERNAL MEDICINE JOURNAL (2020)
Patient-Centered Reduction or Discontinuation of Long-term Opioid Analgesics The HHS Guide for Clinicians
Deborah Dowell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Does Strong Analgesic' Equal Strong Opioid'? Tapentadol and the Concept of μ-Load'
Robert B. Raffa et al.
ADVANCES IN THERAPY (2018)
European Pain Federation position paper on appropriate opioid use in chronic pain management
T. O'Brien et al.
EUROPEAN JOURNAL OF PAIN (2017)
Latin-American guidelines for opioid use in chronic nononcologic pain
Argelia Lara-Solares et al.
PAIN MANAGEMENT (2017)
Guideline for opioid therapy and chronic noncancer pain
Jason W. Busse et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2017)
Opioids Resistance in Chronic Pain Management
Luigi A. Morrone et al.
CURRENT NEUROPHARMACOLOGY (2017)
Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial
Ralf Baron et al.
PAIN PRACTICE (2016)
Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study
Ralf Baron et al.
PAIN PRACTICE (2016)
CDC Guideline for Prescribing Opioids for Chronic Pain-United States, 2016
Deborah Dowell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Orientação para boa prática clínica para opioides no tratamento da dor: os três “Ts” – titulação (teste), ajustes (individualização), transição (redução gradual)
Flaminia Coluzzi et al.
Revista Brasileira de Anestesiologia (2016)
Is tapentadol different from classical opioids? A review of the evidence
Richard M. Langford et al.
BRITISH JOURNAL OF PAIN (2016)
Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial
Robert Buynak et al.
CLINICAL THERAPEUTICS (2015)
Practical Considerations for the Use of Tapentadol Prolonged Release for the Management of Severe Chronic Pain
Manuel J. Sanchez del Aguila et al.
CLINICAL THERAPEUTICS (2015)
Tapering Long-term Opioid Therapy in Chronic Noncancer Pain: Evidence and Recommendations for Everyday Practice
Chantal Berna et al.
MAYO CLINIC PROCEEDINGS (2015)
Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy
M. Niesters et al.
BRITISH JOURNAL OF ANAESTHESIA (2014)
Tapentadol Prolonged Release Versus Strong Opioids for Severe, Chronic Low Back Pain: Results of an Open-Label, Phase 3b Study
Rafael Galvez et al.
ADVANCES IN THERAPY (2013)
Pain sensitivity and opioid analgesia: A pharmacogenomic twin study
Martin S. Angst et al.
PAIN (2012)
Systematic review of tapentadol in chronic severe pain
Rob Riemsma et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia
W. Schroeder et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice
Babette Koegel et al.
NEUROSCIENCE LETTERS (2011)
Antinociceptive and Antihyperalgesic Effects of Tapentadol in Animal Models of Inflammatory Pain
Klaus Schiene et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Efficacy and Safety of Tapentadol Prolonged Release for Chronic Osteoarthritis Pain and Low Back Pain
Bernd Lange et al.
ADVANCES IN THERAPY (2010)
Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee A Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Study
Marc Afilalo et al.
CLINICAL DRUG INVESTIGATION (2010)
Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally-acting analgesics on the horizon?
Hans G. Kress
EUROPEAN JOURNAL OF PAIN (2010)
Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain
Wolfgang Schroeder et al.
EUROPEAN JOURNAL OF PAIN (2010)
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study
Robert Buynak et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain
James E. Wild et al.
PAIN PRACTICE (2010)
Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study
Martin Hale et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
The impact of chronic pain in the community
BH Smith et al.
FAMILY PRACTICE (2001)
Share Paper
